[go: up one dir, main page]

NO20084129L - Pyridin(3,4-B)Pyrazinoner - Google Patents

Pyridin(3,4-B)Pyrazinoner

Info

Publication number
NO20084129L
NO20084129L NO20084129A NO20084129A NO20084129L NO 20084129 L NO20084129 L NO 20084129L NO 20084129 A NO20084129 A NO 20084129A NO 20084129 A NO20084129 A NO 20084129A NO 20084129 L NO20084129 L NO 20084129L
Authority
NO
Norway
Prior art keywords
pyrazinoner
pyridine
compounds
disclosed
methods
Prior art date
Application number
NO20084129A
Other languages
English (en)
Inventor
Michael John Palmer
Andrew Simon Bell
David Louis Brown
David Graham Brown
Christopher Phillips
Michael Brent Tollefson
Robert O Hughes
Dafydd Rhys Owen
Yvette Marlene Fobian
John Nicholas Freskos
Steven Edward Heasley
Eric Jon Jacobsen
Todd Michael Maddux
Brent Virgil Mischke
John Major Molyneaux
Joseph Blair Moon
Jr Donald Joseph Rogier
John Keith Walker
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20084129L publication Critical patent/NO20084129L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives forbindelser og farmasøytisk akseptable salter av forbindelsene, hvor forbindelsene har strukturen av Formel I: hvor R2, R6A, R6Bog R8 er som definert i beskrivelsen. Korresponderende farmasøytiske sammensetninger, fremgangsmåter for behandling, metoder for syntese, og mellomprodukter beskrives også.
NO20084129A 2006-04-21 2008-09-29 Pyridin(3,4-B)Pyrazinoner NO20084129L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79397106P 2006-04-21 2006-04-21
PCT/IB2007/001001 WO2007122466A1 (en) 2006-04-21 2007-04-10 Pyridine[3,4-b]pyrazinones

Publications (1)

Publication Number Publication Date
NO20084129L true NO20084129L (no) 2008-10-29

Family

ID=38431249

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084129A NO20084129L (no) 2006-04-21 2008-09-29 Pyridin(3,4-B)Pyrazinoner

Country Status (42)

Country Link
US (1) US7902195B2 (no)
EP (1) EP2013208B1 (no)
JP (1) JP4436892B2 (no)
KR (1) KR101061328B1 (no)
CN (1) CN101454320B (no)
AP (1) AP2408A (no)
AR (1) AR060525A1 (no)
AT (1) ATE513831T1 (no)
AU (1) AU2007242555B2 (no)
BR (1) BRPI0710658A2 (no)
CA (1) CA2649775C (no)
CR (1) CR10327A (no)
CU (1) CU23777B7 (no)
CY (1) CY1111739T1 (no)
DK (1) DK2013208T3 (no)
DO (1) DOP2007000080A (no)
EA (1) EA014919B1 (no)
EC (1) ECSP088803A (no)
ES (1) ES2366239T3 (no)
GT (1) GT200700035A (no)
HK (1) HK1133875A1 (no)
HR (1) HRP20110539T1 (no)
IL (1) IL194591A (no)
MA (1) MA30352B1 (no)
ME (1) MEP23808A (no)
MX (1) MX2008012456A (no)
MY (1) MY148583A (no)
NL (1) NL2000583C2 (no)
NO (1) NO20084129L (no)
NZ (1) NZ571540A (no)
PA (1) PA8724201A1 (no)
PE (1) PE20080192A1 (no)
PL (1) PL2013208T3 (no)
RS (2) RS51885B (no)
SI (1) SI2013208T1 (no)
SV (1) SV2008003074A (no)
TN (1) TNSN08408A1 (no)
TW (1) TWI337609B (no)
UA (1) UA92637C2 (no)
UY (1) UY30291A1 (no)
WO (1) WO2007122466A1 (no)
ZA (1) ZA200808283B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
SI2101777T1 (sl) * 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
JP5735806B2 (ja) 2008-03-05 2015-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリドピラジノン誘導体インスリン分泌刺激剤、それらを得る方法および糖尿病を治療するためのそれらの使用
JPWO2010041711A1 (ja) * 2008-10-09 2012-03-08 杏林製薬株式会社 イソキノリン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
RS56135B1 (sr) 2010-10-15 2017-10-31 Gilead Sciences Kompozicije i metode za lečenje plućne hipertenzije
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
WO2013030713A1 (en) 2011-08-31 2013-03-07 Pfizer Inc. Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
EP2897964A1 (en) 2012-09-20 2015-07-29 Pfizer Inc. Alkyl-substituted hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
CA2893333C (en) 2012-12-19 2017-10-24 Pfizer Inc. Carbocyclic-and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2956458B1 (en) 2013-02-13 2017-08-09 Pfizer Inc Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
BR112015019276A2 (pt) 2013-02-19 2017-07-18 Pfizer compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
WO2015049616A1 (en) 2013-10-04 2015-04-09 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators
JO3466B1 (ar) * 2013-12-20 2020-07-05 Takeda Pharmaceuticals Co مواد ضابطة لتترا هيدرو بيريدوبيرازينات من gpr6
ES2759277T3 (es) 2014-04-01 2020-05-08 Pfizer Cromeno y 1,1a,2,7b-tetrahidrociclopropa[c]cromeno piridopiracinadionionas como moduladores de gamma-secretasa
MX2016013329A (es) 2014-04-10 2017-01-26 Pfizer 2-amino-6-metil-4,4a,5,6-tetrahidropirano[3,4-d][1,3]tiazin-8a(8h )-il-1,3-tiazol-4-ilamidas.
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
BR112017015693A2 (pt) 2015-02-03 2018-03-20 Pfizer ciclopropabenzofuranil piridopirazinadionas
KR20180004817A (ko) 2015-06-17 2018-01-12 화이자 인코포레이티드 삼환형 화합물 및 포스포다이에스터라제 억제제로서 이의 용도
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
WO2017051294A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
PL3478679T3 (pl) 2016-07-01 2021-10-25 Pfizer Inc. Pochodne 5,7-dihydro-pirolopirydyny do leczenia chorób neurologicznych i neurodegeneracyjnych
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
US11382918B2 (en) * 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
PT3768669T (pt) 2018-03-23 2023-04-24 Pfizer Derivados de piperazina azaspiro
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease
WO2024118524A1 (en) 2022-11-28 2024-06-06 Cerevel Therapeutics, Llc Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1361652A (fr) 1963-06-21 1964-05-22 Ciba Geigy Procédé de préparation de diazines, entre autres de la 2-méthyl-6-hydroxy-7-morpholino-ptéridine
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
TW274550B (no) * 1992-09-26 1996-04-21 Hoechst Ag
JP2000154139A (ja) 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
US6369056B1 (en) * 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6465465B1 (en) * 2000-03-14 2002-10-15 Arzneimittelwerk Dresden Gmbh Process for the treatment of erectile dysfunction and product therefor
CA2438294C (en) * 2001-02-26 2008-10-21 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations
US7067658B2 (en) * 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005040337A2 (en) * 2003-05-20 2005-05-06 The Regents Of The University Of California METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
DE602004026053D1 (no) * 2003-06-26 2010-04-29 Merck Sharp & Dohme
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
EP1833803A4 (en) * 2005-01-03 2009-08-05 Myriad Genetics Inc PHARMACEUTICAL COMPOUNDS COMPRISING CASPASE ACTIVATORS AND INDUCERS OF APOPTOSIS AND THE USE THEREOF
WO2006126082A2 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
US20070155730A1 (en) * 2005-08-26 2007-07-05 Methylgene, Inc. Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase
WO2007112347A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CA2649775C (en) 2006-04-21 2011-05-31 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones

Also Published As

Publication number Publication date
ES2366239T3 (es) 2011-10-18
DOP2007000080A (es) 2007-11-15
MY148583A (en) 2013-04-30
PL2013208T3 (pl) 2011-10-31
ECSP088803A (es) 2008-11-27
AU2007242555A1 (en) 2007-11-01
CR10327A (es) 2008-10-21
JP4436892B2 (ja) 2010-03-24
EA200801998A1 (ru) 2009-04-28
MA30352B1 (fr) 2009-04-01
TW200808794A (en) 2008-02-16
BRPI0710658A2 (pt) 2011-08-16
GT200700035A (es) 2008-02-05
CA2649775A1 (en) 2007-11-01
EP2013208B1 (en) 2011-06-22
KR101061328B1 (ko) 2011-08-31
CU20080194A7 (es) 2011-03-21
EP2013208A1 (en) 2009-01-14
UY30291A1 (es) 2007-11-30
MX2008012456A (es) 2008-10-10
SI2013208T1 (sl) 2011-09-30
HRP20110539T1 (hr) 2011-08-31
US7902195B2 (en) 2011-03-08
US20070249615A1 (en) 2007-10-25
NZ571540A (en) 2010-10-29
WO2007122466A1 (en) 2007-11-01
EA014919B1 (ru) 2011-04-29
AP2408A (en) 2012-05-30
CN101454320B (zh) 2012-12-19
CU23777B7 (es) 2012-02-15
ATE513831T1 (de) 2011-07-15
CY1111739T1 (el) 2015-10-07
DK2013208T3 (da) 2011-08-15
CN101454320A (zh) 2009-06-10
RS20080484A (en) 2009-07-15
HK1133875A1 (en) 2010-04-09
PA8724201A1 (es) 2009-08-26
IL194591A (en) 2012-07-31
AR060525A1 (es) 2008-06-25
RS51885B (en) 2012-02-29
PE20080192A1 (es) 2008-03-01
SV2008003074A (es) 2010-01-12
MEP23808A (en) 2010-06-10
AU2007242555B2 (en) 2010-12-16
NL2000583A1 (nl) 2007-10-23
ZA200808283B (en) 2009-11-25
TWI337609B (en) 2011-02-21
CA2649775C (en) 2011-05-31
AP2008004640A0 (en) 2008-10-31
JP2009534368A (ja) 2009-09-24
TNSN08408A1 (fr) 2010-04-14
NL2000583C2 (nl) 2007-12-14
UA92637C2 (en) 2010-11-25
KR20080110930A (ko) 2008-12-19

Similar Documents

Publication Publication Date Title
NO20084129L (no) Pyridin(3,4-B)Pyrazinoner
NO20091893L (no) Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
WO2007135527A3 (en) Benzimidazolyl compounds
NO20074703L (no) Antibakterielle piperidinderivater
MX2012000414A (es) Derivados piridin-4-ilo.
NO20071617L (no) Indozolonderivater som 11B-HSD1-inhibitorer
NO20066055L (no) Pyridinderivater
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
WO2006126082A3 (en) Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
NO20093200L (no) Tiazolidinderivater
NO20070445L (no) Pyrimidinderivater.
NO20054852L (no) GFAT inhibitorer
WO2008077557A8 (en) 8-ethinylxanthine derivatives as selective a2a receptor antagonists
NO20070089L (no) DPP-IV inhibitorer
NO20091741L (no) Pyrazolinforbindelser som mineralkortikoidreceptorantagonister
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20072831L (no) Imidazo[1,2-A]Pyridinforbindelser, sammensetninger, anvendelser og fremgangsmater relatert dertil
IN2012DN03182A (no)
NO20071658L (no) Alkil-pyridiner som 11-beta-inhibitorer for diabetes
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
NO20073551L (no) Nikotinacetylkolinreseptorligander
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009013501A (es) Compuestos piperidinicos y sus usos.
NO20080033L (no) Kinolinderivater som NK3-antagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application